PepGen Inc. filings document the regulatory record of a clinical-stage biotechnology company developing Enhanced Delivery Oligonucleotide therapies for neuromuscular and neurological diseases. Its Form 8-K disclosures cover financial results, corporate presentations, clinical data updates for PGN-EDODM1, FDA-related regulatory matters involving FREEDOM2-DM1, and other business updates tied to its development pipeline.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board structure, executive compensation and stockholder voting mechanics. Other filings address officer appointments, inducement grants, stock-option plans, option repricing, common-stock compensation arrangements and related governance approvals. Together, the filings outline PepGen’s clinical-development disclosures, capital and equity incentive structure, risk-facing regulatory events and public-company governance practices.
PepGen Inc. reported that on December 8, 2025 it appointed Joseph Vittiglio, Esq. as its Chief Business and Legal Officer. This new executive role combines responsibility for the company's business functions with oversight of legal affairs, adding depth to its leadership team. The company also furnished a related press release as Exhibit 99.1 providing additional detail on the appointment.
PepGen Inc. (PEPG) reported it furnished a press release announcing financial results for the quarter ended September 30, 2025. The company disclosed this under Item 2.02 (Results of Operations and Financial Condition), noting the release is provided as Exhibit 99.1.
The exhibit is furnished, not filed, which affects how it is incorporated by reference. PepGen’s common stock trades on the Nasdaq Global Select Market under the symbol PEPG. The 8-K was signed by CFO Noel Donnelly.
PepGen Inc. (PEPG) reported it furnished a press release announcing financial results for the quarter ended September 30, 2025. The company disclosed this under Item 2.02 (Results of Operations and Financial Condition), noting the release is provided as Exhibit 99.1.
The exhibit is furnished, not filed, which affects how it is incorporated by reference. PepGen’s common stock trades on the Nasdaq Global Select Market under the symbol PEPG. The 8-K was signed by CFO Noel Donnelly.
PepGen Inc. (PEPG) reported Q3 results and strengthened liquidity following a September equity raise. The company ended September 30, 2025 with $163.7 million in cash, cash equivalents and marketable securities. Q3 net loss was $18.0 million (basic and diluted loss per share $0.52), driven by research and development expense of $13.4 million and general and administrative expense of $5.2 million.
In September 2025, PepGen completed an underwritten public offering, issuing 35,937,500 shares (including the underwriters’ option) for net proceeds of $107.6 million. With the improved cash position, management concluded that conditions raising substantial doubt about continuing as a going concern no longer exist and believes current resources will fund operations for at least 12 months; elsewhere the company indicates funding into the second half of 2027.
Clinical updates included PGN‑EDODM1 for DM1: the FREEDOM Phase 1 single‑dose study’s 15 mg/kg cohort showed a mean splicing correction of 53.7% and was generally well tolerated. Dose escalation will conclude at 15 mg/kg. The Phase 2 FREEDOM2 multiple‑dose study is open in Canada and the U.K., with initial 5 mg/kg cohort data expected in Q1 2026. Development of PGN‑EDO51 for DMD was discontinued in May 2025. Shares outstanding were 68,748,224 as of November 5, 2025.
PepGen Inc. (PEPG) reported Q3 results and strengthened liquidity following a September equity raise. The company ended September 30, 2025 with $163.7 million in cash, cash equivalents and marketable securities. Q3 net loss was $18.0 million (basic and diluted loss per share $0.52), driven by research and development expense of $13.4 million and general and administrative expense of $5.2 million.
In September 2025, PepGen completed an underwritten public offering, issuing 35,937,500 shares (including the underwriters’ option) for net proceeds of $107.6 million. With the improved cash position, management concluded that conditions raising substantial doubt about continuing as a going concern no longer exist and believes current resources will fund operations for at least 12 months; elsewhere the company indicates funding into the second half of 2027.
Clinical updates included PGN‑EDODM1 for DM1: the FREEDOM Phase 1 single‑dose study’s 15 mg/kg cohort showed a mean splicing correction of 53.7% and was generally well tolerated. Dose escalation will conclude at 15 mg/kg. The Phase 2 FREEDOM2 multiple‑dose study is open in Canada and the U.K., with initial 5 mg/kg cohort data expected in Q1 2026. Development of PGN‑EDO51 for DMD was discontinued in May 2025. Shares outstanding were 68,748,224 as of November 5, 2025.
PepGen Inc. approved a company‑wide repricing of underwater employee stock options, effective November 4, 2025. Eligible options under the 2020, 2022 and 2024 plans now carry a new exercise price of $4.53. To use the reduced price, employees must remain in service through a defined retention period that ends on the earliest of March 31, 2027 or a qualifying sale event under the applicable plan.
The repricing covers 3,557,903 option shares that previously had exercise prices ranging from $8.89 to $17.91. The Board approved the change on the recommendation of the Compensation Committee; CEO James McArthur recused himself from the vote as an interested director. The company states the goal is to retain and motivate employees during a critical stage, noting that approximately two‑thirds of employee options were underwater at approval.
PepGen Inc.'s Schedule 13G shows that a group of Viking Global entities and three named executives report beneficial ownership of 3,482,434 shares of PepGen common stock, representing 5.1% of the 68,737,224 shares outstanding following the issuer's underwritten offering that closed on September 26, 2025. The filing states the shares are directly owned by Viking Global Opportunities Illiquid Investments Sub-Master LP and are subject to shared voting and shared dispositive power among the reporting persons. The filing includes a joint filing agreement and certifications that the holdings were not acquired to change or influence control.
PepGen Inc. furnished an updated corporate presentation as of October 1, 2025. The company submitted the revised presentation as Exhibit 99.1 under a Regulation FD disclosure, meaning it is being provided for informational purposes and is not treated as filed financial reporting. The presentation is incorporated by reference only if specifically cited in future documents and the company notes that its inclusion does not, by itself, indicate that the information is material.
Oxford Science Enterprises plc reports beneficial ownership of 4,955,388 shares of PepGen Inc. common stock, representing 7.21% of the outstanding shares based on the issuer's stated total of 68,737,224 shares. The reporting person discloses sole voting and sole dispositive power over these shares and indicates the holdings were not acquired to influence control of the issuer.
The statement references the issuer's prospectus supplement for the share count used to calculate the percentage and otherwise confirms no group affiliations, no shared voting or dispositive powers, and that the position is held directly by Oxford Science Enterprises plc.
Oxford Science Enterprises plc reported purchasing 200,000 shares of PepGen Inc. common stock on September 30, 2025 at $3.20 per share in the issuer's public offering. After the purchase, Oxford Science Enterprises beneficially owned 4,955,388 shares. The issuer disclosed there were 68,737,224 shares outstanding as of September 26, 2025, which means Oxford Science Enterprises no longer beneficially owns more than 10% of PepGen's common stock. As a result, Oxford Science Enterprises is no longer subject to Section 16 reporting obligations for PepGen common stock and indicated it will not file further Form 4 or Form 5 reports for these holdings.
PepGen Inc. (PEPG) is the subject of Amendment No. 4 to a Schedule 13D filed by RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. Collectively the Reporting Persons beneficially own 20,099,753 shares, equal to 29.2% of the outstanding common stock based on 68,737,224 shares outstanding. The Fund acquired 9,375,000 shares in PepGen's 2025 public offering at $3.20 per share for an aggregate purchase price of $30.0 million, funded from the Fund's working capital. Certain employee options totaling up to 11,667 shares vest on schedule and a customary 60-day lock-up from the offering applies to directors and officers.
PepGen, Inc. (PEPG) disclosed an underwritten offering and related materials intended to fund its clinical programs and general corporate needs. The company says proceeds are expected to support the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials and for working capital and other general corporate purposes. The filing references an initial registration statement filed June 28, 2024 and declared effective July 8, 2024. The company expects the offering to close on or about September 26, 2025, subject to customary closing conditions. Listed exhibits include an Underwriting Agreement dated September 24, 2025, legal opinion and consent from Goodwin Procter LLP, launch and pricing press releases dated September 24, 2025, and an Inline XBRL cover page. The form is signed by CFO Noel Donnelly on September 26, 2025.